About Isovaleryl-CoA dehydrogenase, mitochondrial
Isovaleryl-CoA dehydrogenase, mitochondrial (IVD) is a protein
from Homo sapiens identified by UniProt accession
P26440, 426 residues long.
MolForge cross-references it against 0 known binders and
93 disease associations.
Target properties
| Protein name | Isovaleryl-CoA dehydrogenase, mitochondrial |
| UniProt accession | P26440 |
| Gene | IVD |
| Organism | Homo sapiens |
| Length | 426 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (93)
Diseases linked to this target (Open Targets).
- isovaleric acidemia · score 0.85
- genetic disorder · score 0.46
- testosterone measurement · score 0.30
- blood metabolite measurement · score 0.27
- vital capacity · score 0.23
- idiopathic pulmonary fibrosis · score 0.23
- interstitial lung disease · score 0.21
- metabolite measurement · score 0.21
- serum metabolite measurement · score 0.21
- isovalerylcarnitine measurement · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P26440-F1 | alphafold | PREDICTED | 93.37 | — |
Amino-acid sequence (426 residues)
MAEMATATRL LGWRVASWRL RPPLAGFVSQ RAHSLLPVDD AINGLSEEQR QLRQTMAKFL QEHLAPKAQE IDRSNEFKNL REFWKQLGNL GVLGITAPVQ YGGSGLGYLE HVLVMEEISR ASGAVGLSYG AHSNLCINQL VRNGNEAQKE KYLPKLISGE YIGALAMSEP NAGSDVVSMK LKAEKKGNHY ILNGNKFWIT NGPDADVLIV YAKTDLAAVP ASRGITAFIV EKGMPGFSTS KKLDKLGMRG SNTCELIFED CKIPAANILG HENKGVYVLM SGLDLERLVL AGGPLGLMQA VLDHTIPYLH VREAFGQKIG HFQLMQGKMA DMYTRLMACR QYVYNVAKAC DEGHCTAKDC AGVILYSAEC ATQVALDGIQ CFGGNGYIND FPMGRFLRDA KLYEIGAGTS EVRRLVIGRA FNADFH
Explore Isovaleryl-CoA dehydrogenase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets